Mentor Capital: A Stealth Cancer Immunotherapy Play

On 7/8/09, in the first of four steps leading to an anticipated merger and name change, Mentor Capital (MNTR.PK) acquired a 20% ownership stake in an innovative clinical stage cancer immunotherapy company, <font>Quantum Immunologics, Inc.</font> (QI).

QI is a privately held company with a goal of initially marketing its active immunotherapy for the treatment of breast cancer in the U.S., in addition to planning for new studies in other types of cancer and a new cancer screening tool. Mentor Capital is providing funding for QI to complete its ongoing, FDA-authorized Phase I/II trials for its experimental metastatic breast cancer treatment, in addition to possible acquisitions and additional clinical trials.